BA3182 / BioAtla - LARVOL DELTA

Key Developments, Operational Updates and Upcoming Milestones (GlobeNewswire) - "Phase 1/2 dose-escalation for conditionally-binding BA3182 (CAB-EpCAM x CAB-CD3 TCE) (NCT05808634) in heavily pretreated patients with unresectable or metastatic adenocarcinoma...Phase 1 dose escalation ongoing and on track for data readout mid-2025; Dosed first three patients at the 300 microgram treatment dose; Cohort expansion data readout anticipated 1H 2026"

P1 data • Trial status • Solid Tumor

Phase 1/2 dose-escalation for conditionally-binding BA3182 (CAB-EpCAM x CAB-CD3 TCE) (NCT05808634) in heavily pretreated patients with unresectable or metastatic adenocarcinoma (GlobeNewswire) - P1 | N=168 | NCT05808634 | Sponsor: BioAtla, Inc. | "Phase 1 dose escalation ongoing and on track with data readout mid-2025, given encouraging continued ongoing dose escalation with increasing antitumor activity. Observed multiple patients with tumor reduction, including a colorectal cancer patient with stable disease for greater than one year. Maximally tolerated dose has not yet been reached. Currently dosing QW cohorts with priming dose and a 100 microgram ongoing treatment dose. Two of three patients have cleared this dose level and we anticipate dosing the 300 microgram cohort once the final patient clears the dose-limiting toxicity (DLT) period on April 8th....Cohort expansion data readout anticipated 1H 2026."

P1 data • Trial status • Solid Tumor

Preliminary Results from a First-in-Human Phase 1 Study of a Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, BA3182, in Pts with Treatment Refractory Metastatic Adenocarcinoma (ESMO-GI 2025) - No abstract available

Clinical • Metastases • P1 data • Oncology

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points (GlobeNewswire) - "The gross proceeds to the Company from the offering are expected to be approximately $9.2 million, before deducting expenses related to the offering payable by the Company. The Company intends to use the net proceeds to be received by it in the offering, along with its existing cash and cash equivalents, to fund its research and development efforts, including to reach several key inflection points for its mid-stage clinical T-Cell Engager (TCE) and Antibody Drug Conjugate (ADC) programs: BA3182 (CAB-EpCAM x CAB-CD3 TCE) Phase 1 dose escalation data (expected readout 2Q25) and Phase 2 expansion data (expected readout 1H26); and mecbotamab vedotin (CAB-AXL-ADC) Phase 2B data in mutated KRAS (mKRAS) non-small cell lung cancer (NSCLC) (expected readout 1H26), to support its partnering activities, and for working capital and other general corporate purposes."

Clinical data • Financing • Non Small Cell Lung Cancer • Solid Tumor

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma. (clinicaltrials.gov) - P1 | N=168 | Recruiting | Sponsor: BioAtla, Inc. | Not yet recruiting ➔ Recruiting | Trial primary completion date: Feb 2025 ➔ Jun 2025

Enrollment open • Metastases • Trial primary completion date • Oncology

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress (GlobeNewswire) - "Phase 1/2 dose-escalation for CAB-EpCAM x CAB-CD3 TCE (BA3182, NCT05808634): On track for full dataset readout of Phase 1 study in 2H 2024; Potential initiation of Phase 2 study in 2H 2024."

P1 data • Trial status • Oncology • Solid Tumor

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) - "Phase 1/2 dose-escalation for CAB-EpCAM x CAB-CD3 TCE (BA3182, NCT05808634): (i) Anticipate completion of Phase 1 with data readout in 2H 2024; (ii) Potential initiation of Phase 2 study in 2H 2024."

New P2 trial • P1 data • Trial status • Solid Tumor

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) - "Phase 2 Trials of Ozuriftamab Vedotin, BA3021: All dosing to be completed before year-end 2023...Squamous Cell Carcinoma of Head and Neck (SCCHN): On track to complete all dosing regimens enrollment by year-end 2023....Phase 1/2 dose-escalation trial of CAB-CTLA-4, BA3071 basket trial: Phase 1 data readout and path forward at upcoming R&D Day on December 13....Phase 1/2 dose-escalation for CAB-EpCAM x CAB-CD3 TCE, BA3182: Progressing Phase 1 study for the treatment of advanced adenocarcinoma; Anticipated completion of Phase 1 and data readout remains on track in 2024."

P1 data • Trial completion date • Trial status • Cervical Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Gynecologic Cancers • Head and Neck Cancer • Hepatocellular Cancer • Kidney Cancer • Liver Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Skin Cancer • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) - "Key Developments, Operational Updates and Upcoming Milestones:...Phase 1/2 dose-escalation for CAB-EpCAM x CAB-CD3 TCE (BA3182): (i) Enrolling Phase 1 study for the treatment of advanced adenocarcinoma; (ii) Anticipated completion of Phase 1 data readout remains on track in 2024."

Enrollment status • P1 data • Oncology • Solid Tumor

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma. (clinicaltrials.gov) - P1 | N=168 | Not yet recruiting | Sponsor: BioAtla, Inc.

Metastases • New P1 trial • Oncology

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma (GlobeNewswire) - "BioAtla, Inc...announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate BA3182 (CAB-EpCAMxCAB-CD3 bispecific T-cell engager) for the treatment of advanced adenocarcinoma. BioAtla plans to initiate and advance a Phase 1 dose-escalation and expansion clinical study in 2023."

IND • New P1 trial • Oncology

BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones (GlobeNewswire) - "Phase 1/2 Dose-Escalation Trial of CAB-CTLA-4 (BA3071) Across Multiple Solid Tumor Types responsive to CTLA-4. Trial ongoing with two of three cohorts completed without any DLTs or SAEs reported...1H23: Phase 2 study of mecbotamab vedotin (BA3011, NCT03425279) in patients with AXL-positive NSCLC. Initiating preparations for discussions with the FDA regarding the potentially registrational part 2 of the study in AXL-positive NSCLC patients. Submission of Phase 2 part 1 interim data for presentation at ASCO. First patient dosed in Phase 2 part 2 study in AXL-positive UPS patients. Interim data in the Phase 2 part 1 ROR-2 positive NSCLC study CAB-EpCAM x CAB-CD3 TCE (BA3182) Phase 1 study initiation. 2H23: Phase 2 part 2 of the BA3011 study in NSCLC patients anticipated initiation. Interim data in the Phase 2 part 1 ROR-2 positive melanoma study. Interim data in the Phase 2 part 1 ROR-2 positive SCCHN study Phase 1 data and Phase 2 initiation in CAB-CTLA-4 (BA3071) study."

New P1 trial • P1 data • P2 data • Trial status • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Sarcoma • Skin Cancer • Soft Tissue Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Undifferentiated Pleomorphic Sarcoma

BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress (GlobeNewswire) - "Phase 1/2 Dose-Escalation Trial of CAB-CTLA-4 (BA3071) Across Multiple Solid Tumor Types responsive to CTLA-4: Trial ongoing with first two cohorts completed without any DLTs or SAEs reported; third cohort (70mg) is on-going with DLT observation period anticipated to conclude by year end....On track for IND submission for CAB EpCAM x CAB-CD3 TCE (BA3182) by year end."

Enrollment status • IND • Oncology • Solid Tumor

BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress (GlobeNewswire) - "Key Developments, Operational Updates and Upcoming Milestones: On track for IND filing for CAB EpCAM x CAB-CD3 bispecific antibody (BA3182) in 4Q22."

IND • Oncology